



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Docket Number (Optional) NEC03P242-KSe		Application Number 10/776,307	
				Applicant(s) Takeo HOSOMI			
				Filing Date February 12, 2004		Group Art Unit 2141	
PATENT DOCUMENTS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
CD	11-167545	06/22/1999	JAPAN			ABS	
↓	2002-244991	08/30/2002	JAPAN			ABS	
↓	2002-222110	08/09/2002	JAPAN			ABS	
↓	2001-125866	05/11/2001	JAPAN			ABS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Japanese Office Action dated September 13, 2006, with English translation.					
EXAMINER <i>Catherine Joyce</i>				DATE CONSIDERED <i>2/6/07</i>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/766,307
Filing Date	January 28, 2004
First Named Inventor	Fang Hu
Art Unit	1642
Examiner Name	Unknown
Attorney Docket Number	SSBC-0001 (121300.00003)

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
cf	1	WO 01/08709 A1	02/08/2001	Anwer, et al.	Entire Document	

**Examiner
Signature**

Catharine Perry

Date	
Considered	

2/6/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Doc#: 4322154

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number		10/766,307
	Filing Date		January 28, 2004
	First Named Inventor		Hu Fang
	Art Unit		1642
	Examiner Name		Unknown
	Attorney Docket Number		SSBC-0001 (121300.00003)

Sheet

2

of

3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CL	2	BISCHOFF JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996 Oct 18;274(5286):373-6.	
	3	BORRELLI MJ, Schoenherr DM, Wong A, Bernock LJ, Corry PM. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells. Cancer Res. 2001 Feb 1;61(3):1113-21.	
	4	GERICKE D, Dietzel F, Konig W, Ruster I, Schumacher L. Further progress with oncolysis due to apathogenic clostridia. Zentralbl Bakteriol [Orig A]. 1979 Mar;243(1):102-12.	
	5	GERICKE D, Dietzel F., Konig, W. Mikrowellenhyperthermie und Onkolyse Durch Clostridien. Naturwissenschaften, Springer Verlag, Berlin, DE. 1975;62(11):541-542.	
	6	GIANNIOS, J. Wt-p53 Gene Treatment Combined with Hyperthermia and Vinorelbine Induce Apoptosis After Ionising-Radiation on Radioresistant Human Colon Adenocarcinoma Cells. Romania Journal of Gastroenterology. 1998;7(2):95-103.	
	7	ITO A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther. 2001 Sep;8(9):649-54.	
	8	LI CY, Dewhirst MW. Hyperthermia-regulated immunogene therapy. Int J Hyperthermia. 2002 Nov-Dec;18(6):586-96.	
	9	OKAMOTO K, Shinoura N, Egawa N, Asai A, Kirino T, Shibasaki F, Shitara N. Adenovirus-mediated transfer of p53 augments hyperthermia-induced apoptosis in U251 glioma cells. Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):525-31.	
	10	QI V, Weinrib L, Ma N, Li JH, Klamut H, Liu FF. Adenoviral p53 gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell line. Int J Hyperthermia. 2001 Jan-Feb;17(1):38-47.	
	11	THYRELL L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002 Feb 14;21(8):1251-62.	

Examiner
Signature

Catherine Joyce

Date

Considered

2/6/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Doc No.:

4322209

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/766,307		
		Filing Date	January 28, 2004		
		First Named Inventor	Hu Fang		
		Art Unit	1642		
		Examiner Name	Unknown		
Sheet	3	of	3	Attorney Docket Number	SSBC-0001 (121300.00003)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CD	12	TOMASOVIC SP, Khodadadian M, Hung MC, Klostergaard J. Hyperthermia enhances the cytotoxicity of National Institutes of Health 3T3 cells transfected with a noncleavable transmembrane pro-tumor necrosis factor deletion mutant. J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):181-7.	
	13	WALTHER W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int J Cancer. 2002 Mar 10;98(2):291-6.	
	14	WANG JH, Yao MZ, Gu JF, Sun LY, Shen YF, Liu XY. Blocking HSF1 by dominant-negative mutant to sensitize tumor cells to hyperthermia. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1454-61.	
	15	WATANABE N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 1988 Feb 1;48(3):650-3.	
	16	ZEH HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. 2002 Dec;9(12):1001-12.	
	17	European Search Report Under Rule 112 EPC, from the European Patent Office, dated May 2, 2006.	

Examiner Signature	<i>Catherine Perez</i>	Date Considered	2/6/07
--------------------	------------------------	-----------------	--------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Doc No.:

4322237



(use as many sheets as necessary)

Sheet	1	of	2 Sheets
-------	---	----	----------

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/766,307
Filing Date	January 28, 2004
First Named Inventor	Hu, et al.,
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-0001 (121300.00002)

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ⁴ - Kind Code ⁵ (if known)				
<i>CF</i>	1.	WO 02/053711	07-11-2002	Holm	Entire Document	

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Transmittal form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2 Sheets

Complete if Known

Application Number	10/766,307
Filing Date	01/28/04
First Named Inventor	Hu, et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-00001 (121300.0003)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CF ↓ V	2.	HAVIV YS, Blackwell JL, Li H, Wang M, Lei X, Curiel DT. Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res. 2001 Dec 1;61(23):8361-5.	
	3.	RIES S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002 Jan 7;86(1):5-11.	
	4.	KRUYT FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther. 2002 Mar 1;13(4):485-95.	
	5.	FALK MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001 Jan-Feb;17(1):1-18.	
	6.	International Search Report, International Application No. PCT/US 04/002330 September 8, 2004	


Examiner Signature	<i>Carther Page</i>	Date Considered	2/6/07
-----------------------	---------------------	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Application Number	10/766,307
Filing Date	01/28/2004
First Named Inventor	Hu, Fang and Wu, Bo
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-0001 (121300.00003)

3617079v1 121300/00003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 5 Sheets

Complete if Known

Application Number	10/766,307
Filing Date	01/28/2004
First Named Inventor	Hu, Fang and Wu, Bo
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-0001 (121300.00003)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CL	5	ALEMANY et al. (2000) Replicative adenoviruses for cancer therapy. Nature Biotechnology 18:723-727	
	6	ANDERSON (1998) Human gene therapy. Nature 392:25-30	
	7	BANCHEREAU et al. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-81	
	8	BARKER AND BERK (1987) Adenovirus proteins from E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107-21	
	9	BISCHOFF et al. (1999) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-6	
	10	BASU AND SRIVASTAVA (2000) Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress & Chaperones 5:443-451	
	11	BERMUDES et al. (2002) Live bacteria as anticancer agents and tumor-selective protein delivery vectors. Curr Opin Drug Discov Devel. 5(2):194-9	
	12	FALK AND ISSELS (2001) Hyperthermia in oncology. Int. J. Hyperthermia 17:1-18	
	13	FONG AND ENGLEMAN (2000) Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18:245-273	
	14	GONG et al. (1997) Induction of anti-tumor activity by immunization with fusion of dendritic and carcinoma cells. Nat. Med. 3:558-561	

Examiner Signature

Catherine Dwyer

Date Considered

2/6/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 5 Sheets

Complete If Known

Application Number	10/766,307
Filing Date	01/28/2004
First Named Inventor	Hu, Fang and Wu, Bo
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-0001 (121300.00003)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ	15	HANAHAN AND WEINBERG (2000). The hallmark of cancer. Cell 100:57-70	
	16	HAVIV et al.(2001) Heat shock and Heat shock protein 70i enhance the oncolytic effect of replicative Adenovirus. Cancer Research 61:8361-8365	
	17	HAWKINS et al. (2002) Oncolytic biotherapy: a novel therapeutic platform. The Lancet Oncology 3:17-26	
	18	HOBOHM (2001) Fever and cancer in perspective. Cancer Immunol Immunother.50: 391-396	
	19	KIRN et al. (2001). Replication-selective virus therapy for cancer: Biological principle, risk management and future directions. Nature 7:781-787	
	20	KUGLER et al. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell. Nat.Med.6:332-336	
	21	LI (1984) Thermal biology and physiology in clinical hyperthermia: current status and further needs. Cancer Res. (Suppl.) 44(8):48865-48935	
	22	LI AND MAK (1985) Induction of heat shock protein synthesis in murine tumors during the development of thermotolerance. Cancer Res. 45(8):3816-3824	
	23	LI et al. (1995) Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int. J. Hyperthermia 11(4): 459-488	
	24	LINDQUIST AND CRAIG (1988) The heat-shock proteins. Annu Rev Genet;22:631-77.	

Examiner
Signature

Catherine Dwyer

Date
Considered

2/6/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5 Sheets

Complete If Known

Application Number	10/766,307
Filing Date	01/28/2004
First Named Inventor	Hu, Fang and Wu, Bo
Group Art Unit	
Examiner Name	
Attorney Docket Number	SSBC-0001 (121300.00003)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CD	25	NESTLE et al. 1998 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat.Med.4:328-332	
	26	RIES AND KIRN (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. British Journal of cancer 86:5-11	
	27	SRIVASTAVA AND JAIKARIA (2001) Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol. Biol. 156:175-186	
	28	VAN RIJN et al.(2000) Heat shock responses by cells treated with azetidine-2-carboxylic acid. Int J Hyperthermia 16:305-318	
	29	WALLEN et al.(1997) Oxidants differentially regulate the heat shock response. Int J Hyperthermia 13:517-24	
	30	WELCH (1992) Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 72(4):1063-81.	
	31	WISCHMEYER (2002) Glutamine and Heat Shock Protein expression. Nutrition 18:225-228	
	32	YING et al. (2001) Innovative cancer vaccine strategies based on the identification of tumor-associated antigen. BioDrugs 15:819-31	
	33	ZYLICZ et al.(2001) HSP70 interactions with the p53 tumor suppressor protein. EMBO Journal 20:4634-4638	

Examiner
Signature*Catherine Joyce*Date
Considered*2/6/07*

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.